Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;65(1):75-81.
doi: 10.1002/mus.27443. Epub 2021 Nov 2.

Identifying a patient-centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis

Pushpa Narayanaswami  1 , Donald B Sanders  2 , Kathie Bibeau  3 , Andrew Krueger  4 , Jurgen Venitz  5 , Jeffrey T Guptill  2
Affiliations

Identifying a patient-centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis

Pushpa Narayanaswami et al. Muscle Nerve. 2022 Jan.

Abstract

Introduction/aims: Data regarding the comparative effectiveness of myasthenia gravis (MG) treatments is not available. We used patient input to identify a patient-centered outcome measure (PCOM) for PROMISE-MG, a comparative effectiveness trial of MG treatments.

Methods: First, a questionnaire survey was administered to 58 people with MG at the patient meeting of the Myasthenia Gravis Foundation of America (MGFA), evaluating the impact of MG-related symptoms and MG treatments on patients' lives. Second, an online focus group of 13 patients with MG was conducted. Third, a potential outcome measure was selected. Fourth, the selected PCOM was evaluated by patients to assess how completely and accurately it captured their experiences with MG.

Results: The patient survey showed that limb weakness had the most impact on patients' lives. Weight gain, mood swings, insomnia, and diarrhea were the most bothersome treatment side effects. Avoiding hospitalization was very important. Focus group participants reported fatigue as one of the most bothersome symptoms and differentiated it from myasthenic weakness. They defined an ideal treatment as having minimal or no side effects and an 80% improvement in symptoms.

Discussion: Based on patient input, the 15-item Myasthenia Gravis Quality of Life-Revised (MG-QOL15R) scale, a validated patient-reported outcome measure (PRO), was selected as the primary PCOM for PROMISE-MG. Avoiding hospitalization and having minimal to no treatment adverse effects were selected as additional outcome measures. The patient-centeredness of a PRO depends on the context of a study: PROs should be evaluated for appropriateness as a PCOM for every study.

Keywords: adverse events; comparative effectiveness; myasthenia gravis; observational study; outcome measure; treatment.

PubMed Disclaimer

References

REFERENCES

    1. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326791/ Co-published by National Institutes of Health (US), Bethesda (MD).
    1. Katzan IL, Thompson NR, Dunphy C, Urchek J, Lapin B. Neurologic provider views on patient-reported outcomes including depression screening. Neurol Clin Pract. 2018;8:86-92.
    1. Muppidi S. Outcome measures in myasthenia gravis. J Clin Neuromuscul Dis. 2017;18:135-146.
    1. Howell D, Molloy S, Wilkinson K, et al. Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors. Ann Oncol. 2015;26:1846-1858.
    1. US Food and Drug Administration. Value and use of patient reported outcomes (PROs) in assessing effects of medical devices. CDRH strategic priorities 2016-2017. https://www.fda.gov/files/about%20fda/published/value-and-use-of-patient.... Accessed September 6, 2021.

Publication types

LinkOut - more resources